Veronica Jara Arias

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK(More)
  • 1